| NBY Stock | | | USD 0.57 0.01 1.79% |
Director
Mr. Xinzhou Li is Director of the Company. He was the Chairman and Executive Director of China Pioneer Pharma since 2013, which, along with its affiliates, is the exclusive distributor of NovaBays NeutroPhase Skin and Wound Cleanser in China and Southeast Asia, as well as NovaBays largest stockholder. Mr. Paul Li has not been appointed to any committees. Mr. Paul Li previously served as the Boards AsiaPacific advisor for over two years. Mr. Paul Li founded China Pioneer Pharma in July 1996, and is responsible for managing its operations and planning, and for formulating the companys strategies. He has more than nineteen years of experience in the pharmaceutical services industry and has more than twentyone years of experience in international trading and management. Prior to China Pioneer Pharma, Mr. Paul Li worked at the Hainan branch of Sumitomo Corporation from 1988 to 1995 since 2015.
| Age | 55 |
| Tenure | 9 years |
| Address | 2000 Powell Street, Emeryville, CA, United States, 94608 |
| Phone | 510 899 8800 |
| Web | https://novabay.com |
Paul Li graduated from Jianghan Petroleum Normal School with a diploma in English and studied at the China Europe International Business School. The Board believes that Mr. Paul Li’s extensive knowledge of NovaBay’s products and of the pharmaceutical industry generally, his leadership of a successful company dedicated to the promotion and marketing of imported pharmaceutical products and medical devices, and his expertise in the international area, are all skills that are important to our Board. In addition, as a representative of NovaBay’s largest stockholder, Mr. Paul Li is uniquely positioned to represent stockholder interests.
NovaBay Pharmaceuticals Management Efficiency
The company has Return on Asset of
(0.3867) % which means that on every $100 spent on assets, it lost $0.3867. This is way below average. In the same way, it shows a return on shareholders' equity
(ROE) of
(2.6383) %, meaning that it generated no profit with money invested by stockholders. NovaBay Pharmaceuticals' management efficiency ratios could be used to measure how well NovaBay Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Tangible Assets is likely to drop to -1.12 in 2024.
Return On Capital Employed is likely to drop to -1.1 in 2024. At this time, NovaBay Pharmaceuticals'
Total Assets are fairly stable compared to the past year.
Non Current Assets Total is likely to rise to about 2
M in 2024, whereas
Other Assets are likely to drop slightly above 461.6
K in 2024.
NovaBay Pharmaceuticals has 2.74
M in debt with debt to equity
(D/E) ratio of 0.14, which may show that the company is not taking advantage of profits from borrowing. NovaBay Pharmaceuticals has a current ratio of 2.54, demonstrating that it is
liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for NovaBay to invest in growth at high rates of return.
Similar Executives
| Found 2 records | DIRECTOR Age |
| Someit MD | Zura Bio Limited | 35 |
| CPA CPA | Sonnet Biotherapeutics Holdings | 75 |
NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops and sells eyecare and skincare products in the United States and internationally. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California. Novabay Pharmaceuticals operates under Biotechnology classification in the United States and is traded on AMEX Exchange. It employs 29 people. NovaBay Pharmaceuticals (NBY) is traded on NYSE MKT Exchange in USA. It is located in 2000 Powell Street, Emeryville, CA, United States, 94608 and employs 24 people. NovaBay Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification.
Management Performance
NovaBay Pharmaceuticals Leadership Team
Elected by the shareholders, the NovaBay Pharmaceuticals' board of directors comprises two types of representatives: NovaBay Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NovaBay. The board's role is to monitor NovaBay Pharmaceuticals' management team and ensure that shareholders' interests are well served. NovaBay Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NovaBay Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Xiaopei Wang, Director | |
| Andrew Jones, Chief Financial Officer, Treasurer | |
| Swan Sit, Independent Director | |
| Mijia Wu, Director | |
| Audrey MD, Chief Director | |
| Paul Freiman, Independent Chairman of the Board | |
| Jeffrey MD, Pres DERMAdoctor | |
| Justin Esq, CEO and President | |
| Yenyou Zheng, Independent Director | |
| Justin Hall, President, Chief Executive Officer, Director | |
| Tommy Law, Interim Controller | |
| Wang Xu, Controller and Senior Manager | |
| Xinzhou Li, Director | |
NovaBay Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NovaBay Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for NovaBay Stock Analysis
When running NovaBay Pharmaceuticals' price analysis, check to
measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to
predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.